Einfluss von Fampridin auf das Arbeitsgedächtnis bei gesunden Probanden

Drug: Fampridine SR;Drug: Placebo

Inclusion Criteria:

- male or female

- generally healthy

- normotensive (BP between 90/60 mmHg and 140/90 mmHg)

- BMI between 19 and 29,9 kg/m2

- aged between 18 and 30 years

- fluent German-speaking

- Informed consent as documented by signature

Exclusion Criteria:

- contraindications to the class of drugs under study, e.g. known hypersensitivity or
allergy to 4-aminopyridine

- use of potassium channel blockers within the last 3 months

- concomitant treatment with OCT 2 inhibitors (e.g. cimetidine, propranolol)

- acute or chronic psychiatric disorder (e.g. major depression, psychoses, somatoform
disorder, suicidal tendency)

- acute cerebrovascular condition

- history of seizures

- risk of lowered seizure threshold (due to e.g. sleep deprivation, withdrawal of
alcohol after alcohol abuse)

- renal impairment

- history of malignant cancers

- walking problems (e.g. due to dizziness)

- other clinically significant concomitant disease states (e.g. hepatic dysfunction,
cardiovascular disease, diabetes, asthma)

- clinically significant laboratory or ECG abnormality that could be a safety issue in
the study

- known or suspected non-compliance

- drug or alcohol abuse

- inability to follow the procedures of the study, e.g. due to language or psychological
problems of the participant

- participation in another study with an investigational drug within the 30 days
preceding and during the present study

- prior participation (less than two years ago) in a study investigating working memory
(notably the n-back task)

- enrolment of the investigator, his/her family members, employees and other dependent
persons

- smoking (>3 cigarettes per day)

- intake of psychoactive drugs (e.g. benzodiazepines, antidepressants, neuroleptics)

- pregnancy or breast feeding